@btweinert.bsky.social
January 2, 2025 at 12:05 PM
Also BioNTech / MSK PDAC study, but I’m not entirely sure what to make of it.
November 18, 2024 at 6:58 PM
Also BioNTech / MSK PDAC study, but I’m not entirely sure what to make of it.
Probably the biggest study to date shows some efficacy in surgically resected melanoma investors.modernatx.com/news/news-de...
Moderna & Merck Announce 3-Year Data For mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in Recurrence-Free Survival & Distant Metastasis-Free Survi...
At a median planned follow-up of the Phase 2b study at 34.9 months, mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 49% and the risk of distant metastasis or d...
investors.modernatx.com
November 17, 2024 at 7:35 PM
Probably the biggest study to date shows some efficacy in surgically resected melanoma investors.modernatx.com/news/news-de...